HC Wainwright & Co. Maintains Buy on Immunic, Raises Price Target to $22

Benzinga Newsdesk www.benzinga.com Positive 77.9%

Neg 0% Neu 0% Pos 77.9%

HC Wainwright & Co. analyst Matthew Caufield maintains Immunic (NASDAQ:IMUX) with a Buy and raises the price target from $5 to $22.